BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

81

203739

BETA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

BETA DRUGS LIMITED performance

Today’s low

Today’s high

₹ 1770.00 ₹ 1810.00
₹ 1790.20

52 week low

52 week high

₹ 1047.62 ₹ 2215.24
₹ 1790.20

Open Price

₹ 1770.00

Prev. Close

₹ 1817.30

Volume (Shares)

2940.00

Total traded value

₹ 52.63

Upper Circuit

₹ 2180.75

Lower Circuit

₹ 1453.85

info

BETA DRUGS LIMITED Share Price Update

As of the latest trading session, BETA DRUGS LIMITED share price is currently at ₹ 1781, which is down by ₹ -36.30 from its previous closing. Today, the stock has fluctuated between ₹ 1770.00 and ₹ 1810.00. Over the past year, BETA DRUGS LIMITED has achieved a return of 39.34 %. In the last month alone, the return has been -3.66 %. Read More...

BETA DRUGS LIMITED fundamentals


  • Market cap (Cr)

    1,712.21

  • P/E Ratio (TTM)

    82.38

  • Beta

    1.08

  • Book Value / share

    114.93

  • Return on equity

    20.67%

  • EPS (TTM)

    21.73

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.00

info icon alternate text
  • Market cap (Cr)

    0.0

  • P/E Ratio (TTM)

    0.0

  • Beta

    0.0

  • Book Value / share

    0.0

  • Return on equity

    0.0%

  • EPS (TTM)

    0.0

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.0

info icon alternate text

BETA DRUGS LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2024 (Values in Cr)
Revenue 197.62
Operating Expense 169.87
Net Profit 21.94
Net Profit Margin (%) 11.10
Earnings Per Share (EPS) 22.82
EBITDA 35.25
Effective Tax Rate (%) 25.61
Particulars MAR 2023 (Values in Cr)
Revenue 157.87
Operating Expense 133.71
Net Profit 18.82
Net Profit Margin (%) 11.92
Earnings Per Share (EPS) 19.57
EBITDA 32.24
Effective Tax Rate (%) 25.34
Particulars MAR 2022 (Values in Cr)
Revenue 124.85
Operating Expense 105.53
Net Profit 14.25
Net Profit Margin (%) 11.41
Earnings Per Share (EPS) 14.82
EBITDA 26.04
Effective Tax Rate (%) 29.36
Particulars MAR 2021 (Values in Cr)
Revenue 79.46
Operating Expense 70.17
Net Profit 6.98
Net Profit Margin (%) 8.78
Earnings Per Share (EPS) 7.26
EBITDA 15.92
Effective Tax Rate (%) 29.35
Particulars MAR 2020 (Values in Cr)
Revenue 65.32
Operating Expense 56.79
Net Profit 7.10
Net Profit Margin (%) 10.86
Earnings Per Share (EPS) 7.49
EBITDA 12.17
Effective Tax Rate (%) 20.67
Particulars MAR 2024 (Values in Cr)
Book Value / Share 163.43
ROE % 26.03
ROCE % 31.58
Total Debt to Total Equity 0.12
EBITDA Margin 20.75
Particulars MAR 2023 (Values in Cr)
Book Value / Share 127.82
ROE % 28.55
ROCE % 32.63
Total Debt to Total Equity 0.19
EBITDA Margin 23.72
Particulars MAR 2022 (Values in Cr)
Book Value / Share 96.05
ROE % 30.85
ROCE % 34.77
Total Debt to Total Equity 0.24
EBITDA Margin 23.64
Particulars MAR 2021 (Values in Cr)
Book Value / Share 71.37
ROE % 18.64
ROCE % 21.20
Total Debt to Total Equity 0.32
EBITDA Margin 21.74
Particulars MAR 2020 (Values in Cr)
Book Value / Share 59.41
ROE % 19.22
ROCE % 19.97
Total Debt to Total Equity 0.43
EBITDA Margin 20.17
Particulars MAR 2024 (Values in Cr)
Book Value / Share 120.67
ROE % 20.67
ROCE % 26.60
Total Debt to Total Equity 0.05
EBITDA Margin 17.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 100.12
ROE % 21.67
ROCE % 27.20
Total Debt to Total Equity 0.07
EBITDA Margin 20.42
Particulars MAR 2022 (Values in Cr)
Book Value / Share 80.57
ROE % 20.23
ROCE % 26.19
Total Debt to Total Equity 0.09
EBITDA Margin 20.86
Particulars MAR 2021 (Values in Cr)
Book Value / Share 65.96
ROE % 11.65
ROCE % 15.59
Total Debt to Total Equity 0.12
EBITDA Margin 20.04
Particulars MAR 2020 (Values in Cr)
Book Value / Share 58.71
ROE % 14.63
ROCE % 16.64
Total Debt to Total Equity 0.17
EBITDA Margin 18.63
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 28.63
Total Assets 254.09
Total Liabilities 254.09
Total Equity 157.11
Share Outstanding 9613790
Price to Book Ratio 10.22
Return on Assets (%) 14.33
Return on Capital (%) 21.67
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 19.16
Total Assets 198.42
Total Liabilities 198.42
Total Equity 122.88
Share Outstanding 9613790
Price to Book Ratio 6.26
Return on Assets (%) 15.48
Return on Capital (%) 22.11
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 17.32
Total Assets 157.85
Total Liabilities 157.85
Total Equity 92.34
Share Outstanding 9613790
Price to Book Ratio 7.02
Return on Assets (%) 15.72
Return on Capital (%) 22.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 10.42
Total Assets 117.50
Total Liabilities 117.50
Total Equity 68.61
Share Outstanding 9613790
Price to Book Ratio 1.82
Return on Assets (%) 9.97
Return on Capital (%) 14.08
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 5.38
Total Assets 107.17
Total Liabilities 107.17
Total Equity 57.11
Share Outstanding 9613790
Price to Book Ratio 0.68
Return on Assets (%) 8.78
Return on Capital (%) 12.22
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 27.19
Total Assets 170.47
Total Liabilities 170.47
Total Equity 116.01
Share Outstanding 9613790
Price to Book Ratio 10.22
Return on Assets (%) 12.86
Return on Capital (%) 18.34
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 17.79
Total Assets 134.04
Total Liabilities 134.04
Total Equity 96.25
Share Outstanding 9613790
Price to Book Ratio 6.26
Return on Assets (%) 14.03
Return on Capital (%) 18.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 15.58
Total Assets 110.89
Total Liabilities 110.89
Total Equity 77.46
Share Outstanding 9613790
Price to Book Ratio 7.02
Return on Assets (%) 12.84
Return on Capital (%) 17.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 8.26
Total Assets 86.23
Total Liabilities 86.23
Total Equity 63.41
Share Outstanding 9613790
Price to Book Ratio 1.82
Return on Assets (%) 8.09
Return on Capital (%) 10.37
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 4.16
Total Assets 82.21
Total Liabilities 82.21
Total Equity 56.43
Share Outstanding 9613790
Price to Book Ratio 0.68
Return on Assets (%) 8.63
Return on Capital (%) 11.12
Particulars MAR 2024 (Values in Cr)
Net Income 48.75
Cash from Operations 30.93
Cash from Investing -13.97
Cash from Financing -7.48
Net change in Cash 9.46
Free Cash Flow 42.54
Particulars MAR 2023 (Values in Cr)
Net Income 41.05
Cash from Operations 23.38
Cash from Investing -19.06
Cash from Financing -2.47
Net change in Cash 1.83
Free Cash Flow 41.59
Particulars MAR 2022 (Values in Cr)
Net Income 34.30
Cash from Operations 29.62
Cash from Investing -21.75
Cash from Financing -0.97
Net change in Cash 6.89
Free Cash Flow 49.05
Particulars MAR 2021 (Values in Cr)
Net Income 15.95
Cash from Operations 18.59
Cash from Investing -5.84
Cash from Financing -7.71
Net change in Cash 5.03
Free Cash Flow 24.35
Particulars MAR 2020 (Values in Cr)
Net Income 11.97
Cash from Operations 8.41
Cash from Investing -15.05
Cash from Financing 8.72
Net change in Cash 2.08
Free Cash Flow 23.71
Particulars MAR 2024 (Values in Cr)
Net Income 29.48
Cash from Operations 21.18
Cash from Investing -11.02
Cash from Financing -0.76
Net change in Cash 9.40
Free Cash Flow 27.62
Particulars MAR 2023 (Values in Cr)
Net Income 25.20
Cash from Operations 10.22
Cash from Investing -5.81
Cash from Financing -2.19
Net change in Cash 2.21
Free Cash Flow 17.13
Particulars MAR 2022 (Values in Cr)
Net Income 20.16
Cash from Operations 18.76
Cash from Investing -12.71
Cash from Financing 1.26
Net change in Cash 7.31
Free Cash Flow 28.37
Particulars MAR 2021 (Values in Cr)
Net Income 9.88
Cash from Operations 11.59
Cash from Investing -3.15
Cash from Financing -4.34
Net change in Cash 4.10
Free Cash Flow 15.03
Particulars MAR 2020 (Values in Cr)
Net Income 8.95
Cash from Operations 6.09
Cash from Investing -14.32
Cash from Financing 9.47
Net change in Cash 1.24
Free Cash Flow 13.60
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

BETA DRUGS LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1790.20 -1.49 redarrow
red-green-graph indicator
12 Bearish
4 Bullish
  • 5 Days 1818.10
  • 26 Days 1820.40
  • 10 Days 1829.80
  • 50 Days 1801.50
  • 12 Days 1831.50
  • 100 Days 1782.10
  • 20 Days 1827.50
  • 200 Days 1683.10
1829.75 PIVOT

First Support

1797.55

First Resistance

1849.50

Second Support

1777.80

Second Resistance

1881.70

Third Support

1745.60

Third Resistance

1901.45

RSI

47.43

ADX

6.04

MACD

11.12

Williams % R

-69.44

Commodity Channel Index (CCI)

-124.22

Date

2025-04-30

Week

1540.00

Same Day

1680.00

Month

2183.00

1 Year

1.08

3 Year

0.86

Over 1 Month

-3.66%

down

Over 1 Year

39.34%

down

Over 3 Months

-5.24%

down

Over 3 Years

25.25%

down

Over 6 Months

-1.52%

down

Over 5 Years

104.08%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

BETA DRUGS LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
32.36%
Promoter Holdings
66.73%
FII
0.9%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Neeraj Batra 6658746.0 (65.96%) Shareholding of Promoter and Promoter Group
Suryavanshi Commotrade Private Limited 680026.0 (6.74%) Public Shareholding
Ashish Kacholia 583800.0 (5.78%) Public Shareholding
Bsas Infotech Limited 128520.0 (1.27%) Public Shareholding
Onkar Singh 107205.0 (1.06%) Public Shareholding
Rahul Batra 41632.0 (0.41%) Shareholding of Promoter and Promoter Group
Varun Batra 34891.0 (0.35%) Shareholding of Promoter and Promoter Group
Aditi Batra 619.0 (0.01%) Shareholding of Promoter and Promoter Group
Heena Batra 619.0 (0.01%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

BETA DRUGS LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
26 Mar 2025 26 Mar 2025 1:20
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

BETA DRUGS LIMITED Share Price

Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017

Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.

The company is primarily engaged in the manufacturing of oncology products. The Company's products range from anti-cancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease.

The Company set up the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new 'state of the art' manufacturing facility for oncology formulations in 2014; developed in-house Albumin bound Paclitaxel in 2015; started in-house API Plant - Adley Labs in 2017.

In October, 2017, the Company came up with a Public Issue of 22,96,000 Equity Shares by raising equity capital aggregating Rs 19.5 Crores.

The Company set up an Oncology Plant in Uzbekistan in 2018. In 2020, the Company launched GEM-RTU, ADLEAP, ADLANTE, BEXINIB; launched 1st Indian Brand of Dasatinib, BEEDAN. In 2021, the Company launched 1st Indian brand of Sunitinib, ADSUNIB.

Parent organization Indian Private
NSE symbol BETA
Founded 2005
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Beta Drugs Ltd?

Answer Field

The share price of Beta Drugs Ltd for NSE is ₹ 1781 and for BSE is ₹ 0.00.

What is the Market Cap of Beta Drugs Ltd?

Answer Field

The market cap of Beta Drugs Ltd for NSE is ₹ 17,12.21 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Beta Drugs Ltd?

Answer Field

The 52 Week High and Low of Beta Drugs Ltd for NSE is ₹ 2215.24 and ₹ 1047.62 and for BSE is ₹ 0.00 and ₹ 0.00.

How to Buy Beta Drugs Ltd share?

Answer Field

You can trade in Beta Drugs Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Beta Drugs Ltd?

Answer Field

The 1 year returns on the stock has been 39.34%.

What is the Current Share Price of Beta Drugs Ltd?

Answer Field

Beta Drugs Ltd share price is for NSE ₹ 1781 & for BSE ₹ 0.00 as on Apr 30 2025 03:27 PM.

What is the Market Cap of Beta Drugs Ltd Share?

Answer Field

The market cap of Beta Drugs Ltd for NSE ₹ 17,12.21 & for BSE ₹ 0.0 as on Apr 30 2025 03:27 PM.

What is the P/E Ratio of Beta Drugs Ltd Share?

Answer Field

As on Apr 30 2025 03:27 PM the price-to-earnings (PE) ratio for Beta Drugs Ltd share is 82.38.

What is the PB ratio of Beta Drugs Ltd Share?

Answer Field

As on Apr 30 2025 03:27 PM, the price-to-book (PB) ratio for Beta Drugs Ltd share is 114.93.

How to Buy Beta Drugs Ltd Share?

Answer Field

You can trade in Beta Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Beta Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Beta Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Beta Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|